1. "Department of Medicine"
Formats
  1. Journal Article (19347)
  2. Meeting Abstract (15822)
  3. Review (1102)
  4. Book Section (924)
  5. Editorial (580)
  6. Research Letter (301)
  7. Conference Paper (299)
  8. Guidelines (285)
  9. Correspondence (226)
  10. Miscellaneous (87)
  11. Book Whole (61)
Groups
  1. Department of Medicine (39034)
  2. Solid Tumor Oncology Division (22035)
  3. Hematologic Malignancies, Division of (13003)
  4. Center for Hematologic Malignancies (10841)
  5. GSK Faculty (10529)
  6. Survivorship Research (9202)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Sergio Giralt (1050)
  4. Miguel-Angel Perales (913)
  5. Clifford Hudis (905)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (642)
  2. 2024 (2141)
  3. 2023 (2451)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2560)

More Years

Publications
  1. Journal of Clinical Oncology (6050)
  2. Blood (3572)
  3. Annals of Oncology (1395)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (890)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6364)
  2. Elsevier Inc. (4610)
  3. American Society of Hematology (3843)
  4. American Association for Cancer Research (2879)
  5. Oxford University Press (2271)
  6. Nature Publishing Group (2080)

More Publishers

Results (39034)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Incorporation of PBRM1, BAP1, TP53 mutation status into the Memorial Sloan Kettering Cancer Center (MSKCC) risk model: A genomically annotated tool to improve stratification of patients (pts) with advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Voss, M. H.; Cheng, Y.; Marker, M.; Kuo, F.; Choueiri, T. K.; Hsieh, J. J.; Reising, A.; Motzer, R. J.; Hakimi, A. A.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in prostate cancer
    Meeting Abstract

    Mazzu, Y. Z.; Gerke, T. A.; Chakraborty, G.; Armenia, J.; Atiq, M. O.; Komura, K.; Yoshikawa, Y.; Lee, G. S. M.; Mucci, L. A.; Kantoff, P. W.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Immunotherapy for biochemically recurrent prostate cancer
    Meeting Abstract

    Madan, R. A.; Karzai, F.; Bilusic, M.; Strauss, J.; Slovin, S. F.; Harshman, L. C.; Theoret, M. R.; Arlen, P. M.; Rauckhorst, M.; Couvillon, A.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Early versus delayed initiation of salvage androgen deprivation therapy and the risk of prostate cancer-specific mortality
    Meeting Abstract

    Mahal, B. A. V.; Chen, M. H.; Renshaw, A. A.; Kantoff, P. W.; D'Amico, A. V.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Cabozantinib for metastatic castration-resistant prostate cancer (mCRPC) following docetaxel: Combined analysis of two phase III trials
    Meeting Abstract

    Pond, G. R.; Sonpavde, G.; Fizazi, K.; De Bono, J. S.; Basch, E. M.; Scher, H. I.; Smith, M. R.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Cabozantinib (C) exposure-response (ER) modeling of efficacy and safety endpoints as a function of clearance in patients (pts) with renal cell carcinoma (RCC)
    Meeting Abstract

    Jonasch, E.; Motzer, R. J.; Escudier, B.; Powles, T.; Markby, D. W.; Nielsen, J.; Lacy, S.; Choueiri, T. K.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Analysis of an online tool to explore evolving practice patterns in renal cell carcinoma (RCC)
    Meeting Abstract

    Kim, W.; Rosenthal, K.; Hutson, T. E.; Motzer, R. J.; Plimack, E. R.; Obholz, K.; Vinther, A.; Rini, B. I.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • S-TRAC trial: Sensitivity analyses of disease-free survival (DFS)
    Meeting Abstract

    George, D. J.; Pantuck, A. J.; Motzer, R. J.; Ravaud, A.; Escudier, B.; Staehler, M. D.; Serfass, L.; Krishnaswami, S.; Casey, M.; Lechuga, M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Impact of new systemic therapies on overall survival (OS) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) in a hospital-based registry
    Meeting Abstract

    Francini, E.; Gray, K. P.; Shaw, G.; Evan, C.; Hamid, A.; Perry, C. E.; Kantoff, P. W.; Taplin, M. E.; Sweeney, C.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Everolimus (E) plus bevacizumab (B) is effective first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) with papillary features (PF): Results from a phase II trial
    Meeting Abstract

    Feldman, D. R.; Lee, C. H.; Molina, A. M.; Knezevic, A.; Chen, Y.; Chaim, J.; Coskey, D. T.; Ged, Y.; Tickoo, S.; Reuter, V. E.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save